SG10201710727UA - Antibody locker for the inactivation of protein drug - Google Patents

Antibody locker for the inactivation of protein drug

Info

Publication number
SG10201710727UA
SG10201710727UA SG10201710727UA SG10201710727UA SG10201710727UA SG 10201710727U A SG10201710727U A SG 10201710727UA SG 10201710727U A SG10201710727U A SG 10201710727UA SG 10201710727U A SG10201710727U A SG 10201710727UA SG 10201710727U A SG10201710727U A SG 10201710727UA
Authority
SG
Singapore
Prior art keywords
locker
inactivation
antibody
protein drug
drug
Prior art date
Application number
SG10201710727UA
Inventor
Tian Lu Cheng
Chih Hung Chuang
Hsiu Fen Ko
yun chi Lu
Original Assignee
Dcb Usa Llc
Univ Kaohsiung Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dcb Usa Llc, Univ Kaohsiung Medical filed Critical Dcb Usa Llc
Publication of SG10201710727UA publication Critical patent/SG10201710727UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG10201710727UA 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug SG10201710727UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361827763P 2013-05-28 2013-05-28

Publications (1)

Publication Number Publication Date
SG10201710727UA true SG10201710727UA (en) 2018-02-27

Family

ID=51989521

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201710727UA SG10201710727UA (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug
SG11201509595PA SG11201509595PA (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201509595PA SG11201509595PA (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug

Country Status (15)

Country Link
US (1) US10633453B2 (en)
EP (1) EP3003370B1 (en)
JP (1) JP6545666B2 (en)
KR (1) KR102182485B1 (en)
CN (1) CN105377297B (en)
AU (1) AU2014274215B2 (en)
CA (1) CA2913051C (en)
EA (1) EA035322B1 (en)
HK (1) HK1221426A1 (en)
IL (1) IL242772B (en)
MX (1) MX2015016329A (en)
SG (2) SG10201710727UA (en)
TW (1) TWI582111B (en)
WO (1) WO2014193973A2 (en)
ZA (1) ZA201508673B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633453B2 (en) 2013-05-28 2020-04-28 Kaohsiung Medical University Antibody locker for the inactivation of protein drug
CA3214529A1 (en) 2013-09-25 2015-04-02 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
DK3083689T3 (en) 2013-12-17 2020-08-03 Genentech Inc Anti-CD3 antibodies and methods of use
AU2015210862B2 (en) 2014-01-31 2020-04-23 Cytomx Therapeutics, Inc Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
US9751946B2 (en) 2014-09-12 2017-09-05 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
MA41374A (en) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF
EP3261669B1 (en) 2015-02-25 2022-08-03 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (en) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 Use of MVA or MVA delta E3L as an immunotherapeutic agent for solid tumors
JP2018520642A (en) * 2015-05-01 2018-08-02 ジェネンテック， インコーポレイテッド Mask anti-CD3 antibody and method of use thereof
CN107847568B (en) 2015-06-16 2022-12-20 豪夫迈·罗氏有限公司 anti-CLL-1 antibodies and methods of use
MX2018002226A (en) 2015-08-28 2018-03-23 Amunix Operating Inc Chimeric polypeptide assembly and methods of making and using the same.
EP4310503A3 (en) 2015-12-30 2024-03-20 Momenta Pharmaceuticals, Inc. Methods related to biologics
CN116440176A (en) 2016-02-25 2023-07-18 纪念斯隆凯特琳癌症中心 Replication-competent attenuated vaccinia virus with thymidine kinase deficiency and with or without human FLT3L or GM-CSF expression
AU2017222687B2 (en) 2016-02-25 2022-02-24 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human Flt3L and use thereof as immuno-therapeutic agents against solid tumors
WO2017165306A1 (en) * 2016-03-20 2017-09-28 Middle Tennessee State University ASSAY FOR HIGH-THROUGHPUT lDENTIFICATION OF THERAPEUTIC COMPOUNDS
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP3458588A4 (en) * 2016-05-18 2020-01-15 Voyager Therapeutics, Inc. Modulatory polynucleotides
CN107446016A (en) * 2016-05-30 2017-12-08 上海交通大学 A kind of cell-penetrating peptide of Stearate Modified and its preparation and application
WO2017211278A1 (en) * 2016-06-06 2017-12-14 Asclepiumm Taiwan Co., Ltd Antibody fusion proteins for drug delivery
PE20191131A1 (en) * 2016-11-03 2019-09-02 Bristol Myers Squibb Co ACTIVABLE CYTOTOXIC T LYMPHOCYTE 4 ANTI ANTIGEN (CTLA-4) ANTIBODIES AND THEIR USES
AU2017361081A1 (en) 2016-11-15 2019-05-23 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
KR20190089034A (en) * 2016-12-09 2019-07-29 시애틀 지네틱스, 인크. Antibodies shielded by coiled coils
CA3048467A1 (en) * 2016-12-29 2018-07-05 Development Center For Biotechnology Klk6-mediated cns-specific antibody prodrug activation
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
US11939385B2 (en) * 2017-05-16 2024-03-26 ALX Oncology Inc. Activatable antibodies and methods of use thereof
AU2018375375A1 (en) 2017-12-01 2020-05-28 Seagen Inc. CD47 antibodies and uses thereof for treating cancer
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
KR102245552B1 (en) * 2018-02-28 2021-04-29 부산대학교 산학협력단 Nanodrug Composites, preparation method therof, and use for the same
EP3765047A4 (en) * 2018-03-13 2022-01-12 Memorial Sloan-Kettering Cancer Center Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy
JP7425049B2 (en) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． DLL3 binding protein and method of use
TW202112354A (en) 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 Masked antibody formulations
US20220306727A1 (en) 2019-06-05 2022-09-29 Seagen Inc. Methods of Purifying Masked Antibodies
WO2023288236A1 (en) 2021-07-14 2023-01-19 Seagen Inc. Antibody masking domains
WO2023049825A1 (en) 2021-09-24 2023-03-30 Seagen Inc. Improved antibody masking domains
WO2023064945A2 (en) * 2021-10-15 2023-04-20 Harpoon Therapeutics, Inc. Conditional activation of immunoglobulin molecules
WO2023222580A1 (en) 2022-05-16 2023-11-23 Byondis B.V. Novel masked antibodies

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
GB9322156D0 (en) 1993-10-27 1993-12-15 Univ Newcastel Upon Tyne Activation of molecules
WO1996034892A1 (en) 1995-05-03 1996-11-07 Bioenhancements Ltd. Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
US7238505B2 (en) 2000-10-04 2007-07-03 Ahram Biosystems Inc. Immobilized DNA polymerase
US7524502B2 (en) * 2001-11-12 2009-04-28 Merck Patent Gmbh Modified anti-TNF alpha antibody
CA2475388A1 (en) 2002-02-14 2003-08-21 William J. Rutter Chimeric molecules for cleavage in a treated host
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
CA2524325C (en) 2003-06-09 2017-08-01 John A. Mcintyre Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
GB0404187D0 (en) 2004-02-25 2004-03-31 Biotransformations Ltd Binding agents
MX2007004374A (en) * 2004-10-12 2008-01-29 Amprotein Corp Chimeric protein.
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0605702D0 (en) 2006-03-21 2006-05-03 Biotransformations Ltd Materials and methods for immune cell stimulation
AT503902B1 (en) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
WO2009021754A2 (en) 2007-08-15 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
GB0716160D0 (en) 2007-08-17 2007-09-26 Biotransformations Ltd Materials and methods for treating cancers which express folate receptors
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
JP5448397B2 (en) * 2007-09-07 2014-03-19 キヤノン株式会社 Substrate probe, detection method of enzyme activity by multiple nuclear magnetic resonance method, and imaging method of enzyme activity
US20100189727A1 (en) 2008-12-08 2010-07-29 Tegopharm Corporation Masking Ligands For Reversible Inhibition Of Multivalent Compounds
RU2636046C2 (en) * 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Modified antibodies composition, methods of production and application
BRPI1011384A2 (en) * 2009-02-23 2016-03-15 Cytomx Therapeutics Inc proproteins and their methods of use
RU2015153109A (en) 2009-09-16 2019-01-15 Дженентек, Инк. SUPERSPIRAL AND / OR BINDING PROTEIN COMPLEXES AND THEIR APPLICATIONS
ES2617777T5 (en) * 2010-04-23 2022-10-13 Hoffmann La Roche Production of heteromultimeric proteins
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
RU2013110876A (en) 2010-08-24 2014-09-27 Рош Гликарт Аг ACTIVATED SPECIFIC ANTIBODIES
WO2012048332A2 (en) 2010-10-08 2012-04-12 John Williams A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
SG195077A1 (en) * 2011-06-22 2013-12-30 Hoffmann La Roche Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CN107266574A (en) 2012-03-30 2017-10-20 拜尔健康护理有限责任公司 The antibody of albumen enzyme adjustment
WO2013163631A2 (en) 2012-04-27 2013-10-31 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
AU2013278075B2 (en) 2012-06-22 2018-05-17 Cytomx Therapeutics, Inc. Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof
WO2014052462A2 (en) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
EP2970498A4 (en) 2013-03-15 2016-11-23 Bayer Healthcare Llc Pro-drug antibodies against tissue factor pathway inhibitor
US10633453B2 (en) 2013-05-28 2020-04-28 Kaohsiung Medical University Antibody locker for the inactivation of protein drug
HRP20220553T1 (en) 2013-07-25 2022-06-10 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
CA3214529A1 (en) 2013-09-25 2015-04-02 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
DE102014201538A1 (en) 2014-01-29 2015-07-30 Robert Bosch Gmbh A method for driving a parking lot management system for at least one parking lot and parking lot management system for at least one parking lot

Also Published As

Publication number Publication date
CN105377297A (en) 2016-03-02
TWI582111B (en) 2017-05-11
TW201520230A (en) 2015-06-01
EP3003370A4 (en) 2017-01-25
MX2015016329A (en) 2016-07-20
AU2014274215B2 (en) 2019-02-28
CN105377297B (en) 2019-09-17
WO2014193973A3 (en) 2015-02-19
SG11201509595PA (en) 2015-12-30
CA2913051C (en) 2023-09-05
EA035322B1 (en) 2020-05-28
CA2913051A1 (en) 2014-12-04
AU2014274215A1 (en) 2015-12-03
ZA201508673B (en) 2017-05-31
US20160185875A1 (en) 2016-06-30
EP3003370A2 (en) 2016-04-13
EA201592049A1 (en) 2016-04-29
JP2016520614A (en) 2016-07-14
IL242772B (en) 2020-04-30
US10633453B2 (en) 2020-04-28
JP6545666B2 (en) 2019-07-17
WO2014193973A2 (en) 2014-12-04
EP3003370B1 (en) 2020-01-22
KR102182485B1 (en) 2020-11-25
HK1221426A1 (en) 2017-06-02
KR20160032041A (en) 2016-03-23

Similar Documents

Publication Publication Date Title
HK1221426A1 (en) Antibody locker for the inactivation of protein drug
IL274646A (en) Integrated continuous manufacturing of therapeutic protein drug substances
IL243976A0 (en) Kdm1a inhibitors for the treatment of disease
ZA201601430B (en) Insecticidal proteins and methods for their use
ZA201509369B (en) Insecticidal proteins and methods for their use
IL252015A0 (en) Antibody drug conjugates
IL250189A0 (en) Anti-cdh6 antibody drug conjugates
EP3019491A4 (en) Kinase inhibitors for the treatment of disease
SG10202002153PA (en) Glycoengineered antibody drug conjugates
CL2014000864S1 (en) Medication container
PT2986633T (en) Methods for the expression of peptides and proteins
CL2014000866S1 (en) Medication container
HK1212713A1 (en) Therapeutic uses for vegfr1 antibodies vegfr1
HK1222548A1 (en) Pharmaceutical combinations for the treatment of cancer
HK1219961A1 (en) Human anti-ifn-alpha antibodies
GB201318686D0 (en) Pharmaceutical preparations
GB201301721D0 (en) Pharmaceutical Preparations
PT3016977T (en) Human anti-il-32 antibodies
SG10201800592SA (en) Medicament comprising anti-phospholipase d4 antibody
EP3095462A4 (en) Therapeutic pharmaceutical composition employing anti-slc6a6 antibody
GB201319024D0 (en) Reduced viscosty protein pharmaceutical formulations
AU2013904239A0 (en) Pharmaceutical combinations for the treatment of cancer
UA28963S (en) MEDICINE BOTTLE
TH1501000860A (en) Solid pharmaceutical preparations containing levythyrosine.
UA26185S (en) MEDICINE BOTTLE